Identification of Highly Frequent *TP53* Germline Variations in a Cohort of Head and Neck Cancer Cases

Sadia Ajaz [1*], Rabbia Muneer[1], Aisha Siddiqa[2], Muhammad Ali Memon[2]

[1.] **Dr. Panjwani Center for Molecular Medicine and Drug Research (PCMD), International Center for Chemical and Biological Sciences (ICCBS), University of Karachi, Karachi-75270, Pakistan.**

[2.] **Atomic Energy Medical Centre (AEMC), Jinnah Postgraduate Medical Centre (JPMC), Karachi, Pakistan.**

[*]**Corresponding Author:**

Sadia Ajaz, *Ph. D.*

E-mail: sadiaajaz.pcmd@iccs.edu

Abstract

TP53 tumour suppressor gene inactivation plays a significant role in molecular pathology of cancers. *TP53* germline mutations/variations increase the risk of developing multiple primary cancers. However, the role of such *TP53* genetic alterations in head and neck cancers (HNCs) is not well-established. HNCs comprise one of the most frequent cancers in Karachi, Pakistan. The pilot study reports the investigation of germline mutations in *TP53* gene in a cohort of 30 HNC patients from Pakistan. Blood samples were collected and genomic DNA was extracted from white blood cells. After quality control, amplification of seven selected exons along with their splice sites, two intronic regions (introns 2-3 and 3-4), and 3'UTR were carried out. Sanger sequencing was carried out in order to identify germline variations. Comparison with wild type sequence revealed 11099C>G (intron 2-3) variation in 90%, PIN3 duplication (intron 3-4) in 95%, and exon 4 C>G (rs1042522) alteration in 93.4% of the cases. In 3'UTR, gDNA7669374_5delCC was found in 13.4% of the analyzed cases. In conclusion, we report three highly frequent germline variations and a newly discovered variation in 3'UTR in *TP53* germline DNA of head and neck cancer patients from Pakistan. These results shall contribute in delineating the genetic component of head and neck cancers.

Introduction

TP53 is a tumor suppressor gene. Its locus is 17p13.1. It covers ∼19.15 kb of DNA and transcript length is 2,724 bp (Ensembl, 2019). *TP53* encodes for p53, which is known as the guardian of the genome (Bergh, 1999). It is a transcription factor and a tumor suppressor protein. It consists of 12 exons, in which 9 exons constitute the coding sequence of the p53. It is made up of 393 amino acids. It plays a key role in various signaling pathways that regulate the cellular response to stress and damage. It is the key regulator of apoptosis, autophagy, angiogenesis, differentiation, DNA repair, ferroptosis, metabolism, proliferation and senescence (Monti *et al.,* 2020)

p53 consists of several domains as shown in Figure 1. These include Amino Terminal domain (AT), Proline Rich Domain (PRD), folded DNA Binding Domain (DBD), a short region of Nuclear Localization Signal (NLS), C-Terminal regulatory Domain (CTD) that contains tetramerization or Oligomerization Domain (OD), and Basic Repression (BR) domain (Raj and Attardi, 2017). Genetic alterations in exons and the intronic regions therein lead to aberrations in protein function.

TP53 is well known for germline and somatic variations in inherited and sporadic tumors, respectively (Bouaoun *et al.,* 2016). In head and neck cancer (HNC) patients, *TP53* mutation is a common somatic alteration (Zhou, Liu, and Myers, 2016). However, little is known about the germline *TP53* variations in head and neck carcinogenesis. The present study addresses this gap. It analyzes functionally significant exons, known-highly polymorphic introns and 3'UTR of *TP53* gene in HNC patients.

Methodology

Ethics Statement:

The study was carried out in accordance with Declaration of Helsinki (WMA, 2018). Ethical approval of the study and participants' informed consent have been published earlier (Ajaz et al., 2021).

Blood sampling and DNA extraction:

In this discovery study, samples from 30 HNC patients were collected. DNA extraction was carried out by using standard phenol/chloroform method (Russell and Sambrook, 2001).

Identification of germ-line variations

The amplification of targeted sequence was done through PCR and the amplicons were purified by isopropanol.

PCR for *TP53* germline variations

Thermo Fisher reagents (Thermo Fisher Scientific, Inc.) were used for PCRs. Touch down PCRs were carried out in a thermal cycler (Kyratec®). Primer sequences for the selected exons and introns are listed in Table 1. Total volume for each PCR was 25μL. PCR conditions for each exon are given as follows:

TP53 **Exons 2 & 3; Introns 2-3 & 3-4:** 1X PCR Buffer with $(NH_4)_2SO_4$, 1.1mM $MgCl_2$, 0.2mM dNTPs, 0.5U of *Taq polymerase*, 0.4μM *TP53* exons/introns 2, 3 & 4 forward and reverse primers, and 80ng total genomic DNA.

TP53 **Exon 4**: 1X PCR Buffer with $(NH_4)_2SO_4$, 1.5mM $MgCl_2$, 0.2mM dNTPs, 0.5U of *Taq polymerase*, 0.4μM *TP53* exon 4 forward and reverse primers, and 100ng total genomic DNA.

TP53 **Exon 6**: 1X PCR Buffer with $(NH_4)_2SO_4$, 1.5mM $MgCl_2$, 0.2mM dNTPs, 0.5U of *Taq polymerase*, 0.4μM *TP53* exon 4 forward and reverse primers, and 100ng total genomic DNA.

TP53 **Exons 8 & 9:** 1X PCR Buffer with $(NH_4)_2SO_4$, 0.87mM $MgCl_2$, 0.2mM dNTPs, 0.5U of *Taq polymerase*, 0.4μM *TP53* exons 8 & 9, forward and reverse primers, and 80ng total genomic DNA.

TP53 **Exon 11**: 1X PCR Buffer with $(NH_4)_2SO_4$, 1.15mM $MgCl_2$, 0.2mM dNTPs, 0.5U of *Taq polymerase*, 0.4µM *TP53* exon 11 forward and reverse primers, and 100ng total genomic DNA.

PCR thermal cycling conditions for all exons were the same with initial denaturation at 94ºC for 2min followed by 20 cycles (94 ºC for 30 sec. 63 ºC for 45 sec. and 72 ºC for 1 min), 30 cycles (94 ºC for 30 sec. 60 ºC for 45 sec. and 72 ºC for 1 min) and final elongation at 72 ºC for 10 min. Five µL of amplified product was loaded on 2.5% gel and observed in Azure gel imaging system under UV light.

Sanger sequencing was done commercially and sequences were compared with reference *TP53* sequence (HGNC:11998)

Results

Demographic and Clinicopathological Characteristics of HNC Patients

The study analyzed DNA samples from 30 HNC patients . In this pilot study 53.3% (16/30)% patients were male, while 46.7% (14/30)% patients were female.

Age-wise comparison showed that 69% patients were above the age of 40 years and 31 % patients were less than or equal to the age of 40 years. In addition, 65% of the analyzed patients reported addiction to betel leaf, betel nut, tobacco, and or smokeless tobacco, while 35% reported no such addiction.

Among patients, 58.6% had oral cavity cancer, followed by 17.2% cases each of oropharyngeal and nasopharyngeal carcinoma. Squamous cell carcinoma was the most frequently reported histological sub-type in this studied cohort (83.3.2%).

Family history assessment showed that out of 30 patients, one patient had positive history of head and neck cancer in the family.

Identification of Mutations and Polymorphisms in *TP53* Gene

30 HNC patients were sequenced for specific exons of *TP53* through Sanger sequencing. The results for *TP53* germline variations are summarized in Table 2.

The following germline variants were identified in the patients:

11099C>G (intron 2-3) variation:

A polymorphism was identified in the intron 2-3 of *TP53* gene in 90.5% of the analyzed cases (Figure 2)

Figure 2: Electropherogram of Sanger sequencing for *TP53* intron 2-3 (arrows represent the site of polymorphism). A- homozygous C/C, B- heterozygous C/G, C-homozygous G/G.

Polymorphism in Intron 3 (PIN3) Duplication:

PIN3 duplication was detected in 95.2% of the head and neck cancer cases (figure 3)

Figure 0: Electropherogram of Sanger sequencing for *TP53* polymorphism within intron 3 (PIN3), that is 16 bp duplication (5 -ACCTGGAGGGCTGGGG-3). Arrows represent the site of polymorphism.

Exon 4 Codon 72 Polymorphism (rs1042522):

A reported polymorphism in exon 4, rs 1042522, was identified in 93.4% of the cases (figure 4)

Figure 4: Electropherogram of Sanger sequencing for *TP53* exon 4 codon 72 polymorphism (arrows represent the site of polymorphism). A-heterozygous (C/G), B- homozygous (C/C), homozygous (G/G).

3'UTR gDNA7669374_5delCC

In the analyzed cases, 3'UTR gDNA7669374_5delCC was detected in 13.4% of the cases (figure 5)

Figure 5: Electropherogram of Sanger sequencing for *TP53* exon 11 and 3'UTR, insertion and deletion mutations. A-Homozygous wildtype, B-represents the mutation sites.

Discussion

Mutant p53 promotes the growth of cancerous cells which leads to cancer progression. It has also an association with inefficient therapeutic response (Sabapathy and Lane, 2018).

Amino Terminal Domain (Introns 2-3 and 3-4)

TP53 exon 2 encodes for Amino Terminal (AT) domain of p53, that contains translational ATG start codon (Phang *et al.,* 2015). The AT domain consists of two short amphipathic motifs,

termed as Transactivation Domains, "TAD1" and "TAD2", which contain 1–40 and 41–61amino acid residues, respectively (Krois, Dyson, and Wright, 2018; Sabapathy and Lane, 2018).

TAD forms binding sites for various regulatory proteins. The TAD motif fold into ordered helical structure upon binding to regulatory partners (Krois *et al.,* 2016). These interactions are important for p53 function as well as negative regulation, proteasomal degradation and stabilization, and p53 targeted genes activation. As the cellular stress level increases, phosphorylation of TAD also increases as shown in Figure 3.2 (Krois *et al.,* 2018).

Deletion and rearrangement in TAD domain results in loss of p53 protein expression. Translation of p47 (an amino terminal truncated 47 kDa protein) is started from another start codon located in *TP53* exon 4 (Phang *et al.,* 2015).

Proline Rich Domain [exon 4 C>G (rs1042522)]

Proline rich region (PRD) is encoded by exon 3 and 4 of *TP53*. PRD connects the TAD to DBD. It carries 12 proline amino acids. It promotes protein–protein interactions in signal transduction. Other domains of p53 are conserved while, PRD is not conserved. PRD plays important role in apoptosis and growth suppression (Chillemi *et al.,* 2017).

DNA Binding Domain [exons 6 and8]

DNA Binding Domain (DBD) is encoded by *TP53* exons 5 to 8 (Kadia *et al.,* 2016). It consists of 200 amino acids. DBD regulates the transactivation and DNA binding functions of p53, other functions include DNA binding ability, apoptosis, cell cycle arrest, and RAS-induced senescence as well as tumor suppressor activity. Thus, it plays crucial role in tumor suppression (Hanel *et al.,* 2013).

Almost 80% of all *TP53* mutations occur within DBD (Bouaoun *et al.,* 2016). P53 DBD mutants have lost the potential to trans-activate its target genes (Lee *et al.,* 2012). Therefore, mutations in the DBD results in loss of p53 function.

TP53 germline mutations in the DBD predisposes to spontaneous cancer development typically in individuals with Li-Fraumeni syndrome (LFS). LFS is an inherited disease, that predisposes to a wide range of cancers (Hanel *et al.,* 2013).

Mutant DBD produces "Dominant Negative" effect. If the mutant p53 interferes the wild type (WT) protein activities in the heterozygous state and inactivates them is known as Dominant Negative effect, which is represented in Figure 12. This dominant negative effect occurs at the early stages of cancer. Mutation in one allele reduces the overall function of p53 and results in haploinsufficieny (Sabapathy, 2015).

In the later stages of cancer progression, after the Loss of Heterozygosity (LOH), mutant p53 is unable to recognize its target sequence resulting in the loss of WT functions. Some p53 mutant have acquired novel Gain of Function (GOF) activities, which in turn increases cancer progression, metastasis and genomic instability.

The oncogenic functions of mutant p53 includes, angiogenesis, chemo-resistance, invasion, migration, mitogenic defects, proliferation, scattering, stem cell expansion, survival, and tissue remodeling. These wide variety of responses showed that mutant p53 can function through several different pathways (Muller and Vousden, 2013). Thus, p53 is also called "contrived" oncogene (Sabapathy, 2015).

Carboxyl Terminal Domain

TP53 exons 9 to 11 encodes for the carboxyl terminal domains of p53. It consist of an Oligomerization Domain (OD) and Basic Repression domain (BR) (Joruiz and Bourdon, 2016).

Oligomerization Domain (OD)

The Oligomerization Domain (OD) is encoded by *TP53* exons 9 to 10. It comprises of 325–356 amino acids of p53. These amino acids are important for the p53 tetramerization, which is the critical step for tumor suppressor activity (Sabapathy and Lane, 2018). OD undergoes alternative splicing and posttranslational modifications (Kiraz *et al.,* 2016).

Various *TP53* germline mutations have been identified within the OD that has an association with Li-Fraumeni syndrome. The connection between OD mutations and LFS shows the importance of OD in maintaining the cellular homeostasis (Fischer *et al.,* 2016).

Consequently, mutation in the OD acquired Loss of Function (LOF) of p53. These OD mutant proteins have lost the potential to function as tumor suppressors or trans-activate the target genes (Fischer *et al.,* 2016). Mutations that disturb p53 tetramerization also abrogate DNA binding, hence reducing the target gene activation (DiGiammarino *et al.,* 2002). Conventional therapies

may not be effective for the patients with OD mutations. These patients rely on p53-dependent cytostatic or cytotoxic effect for the eradication of cancer cells (Sabapathy and Lane, 2018). Rare OD mutations are also present in sporadic cancers (Bouaoun *et al.,* 2016).

Basic Repression domain

TP53 exons 10 and 11 encodes the Basic Repression (BR) domain. It is rich in basic amino acid lysine. It undergoes several posttranslational modifications including, acetylation, phosphorylation, sumoylation, methylation, ubiquitinylation, neddylation, etc. It regulates p53 stability and activity (Joruiz and Bourdon, 2016).

Mutations in *TP53* downregulates apoptosis that leads to unstable genome and results in loss of tumor suppression activity (Muller and Vousden, 2013). These alterations also induce gain of function mutations that facilitate tumor progression as well as metastasis (Liu *et al.,* 2019).

AT domain, DBD, and OD are the most common sites of mutations (Liu *et al.,* 2019). Mutations in the AT domain usually result in the disruption of complete p53 expression. Sporadic human cancers containing AT mutations are usually more sensitive to treatment (Phang *et al.,* 2015).

In Pakistani population, we determined polymorphism within *TP53* intron 3 (PIN3) and a novel C/G polymorphism in intron 2 of *TP53*. *TP53* polymorphisms may be critical for cancer progression.

PIN3 is a 16 bp (5′-ACCTGGAGGGCTGGGG-3′) duplication. The intron 3 is relatively small in size i.e. 93 bp. The 16 bp insertion in intron 3 may lead to 17% increase in length. This insertion alters gene expression and protein function (Winiecka-Klimek *et al.,* 2014). PIN3 has an association with breast and colorectal cancer (Costa *et al.,* 2008; Sagne *et al.,* 2013).

PIN3 heterozygotes are responsible for *TP53* haploinsufficieny (Winiecka-Klimek *et al.,* 2014). *TP53* haploinsufficieny was previously reported in different populations. It was 31% in Asian population (Guleria *et al.,* 2012; Paskulin *et al.,* 2012), 25% in South American population and 20% in European population (Gemignani *et al.,* 2004).

We have also found polymorphism in *TP53* exon 4 at codon 72 in local HNC population (Matlashewski *et al.,* 1987). This SNP substitutes arginine with proline thus affects p53 protein

structure (Pietsch *et al.,* 2006). This polymorphism presents in the proline rich region of p53 that regulates apoptosis and growth suppression of cell. P53 protein that contain Arg at codon 72 is more likely to be degraded by E6 protein of HPV11, HPV16, HPV18, and thus facilitates the oncogenic consequence of HPV (Storey *et al.,* 1998).

Another study found that Arg/Arg homozygotes induce apoptosis more efficiently as compared to Pro/Pro homozygotes that play role in the arrest of cell cycle in G1 phase (Pim and Banks, 2004). Codon 72 polymorphism has an association with lung, breast, and bladder cancer (Fan *et al.,* 2000; Langerød *et al.,* 2002). However, another study reports that Arg allele has a significant protective effect in the development of HNC (Cortezzi *et al.,* 2004).

TP53 mutations mostly occur in the DBD. This domain contains 540 nucleotides with numerous recurring hotspot mutations including frameshift, nonsense, silent, and missense mutations while the missense mutation is more frequent in DBD. DBD mutant p53 is relatively a stable protein with the loss of WT functions. In addition to LOF, DBD mutations also gain additional oncogenic properties. Exon 8 was identified as the most frequently affected site in DBD (Liu *et al.,* 2019).

In exon 8 we have identified a polymorphism at codon 285 in which G is replaced with A. It was previously reported as GAG to AAG (glutamate to lysine) substitution. This polymorphism has an association with invasive breast carcinoma (Osborne *et al.,* 1991).

OD plays important role in tetramerization of p53. OD mutations often act as LOF mutations. Patients with OD mutations are less sensitive to therapies. These patients mostly dependent on p53-mediated cytotoxicity (Sabapathy and Lane, 2018). In exon 11 novel insertion and deletion mutations have identified but these mutations require validation by reverse sequencing.

The position and the type of mutation in *TP53* is important and it has differential effects on prognosis (Canale *et al.,* 2017). Different p53 mutant forms have several important functional differences. PIN3 as well as codon 72 are the most commonly reported polymorphisms.

Conclusion

In conclusion, we report three highly frequent germline variations and a newly discovered variation in 3'UTR in *TP53* germline DNA of head and neck cancer patients from Pakistan.

Further functional analysis is recommended to assess the effect of these variations in cancer etiology and pathology.

Conflict of Interest:

The authors declare no conflict of interest.

References

Acha-Sagredo, A., Ruesga, M. T., Rodriguez, C., Aguirregaviria, J. I., de Pancorbo, M. M., Califano, J. A., and Aguirre, J. M. (2009). P53 mutation is rare in oral mucosa brushings from patients previously treated for a head and neck squamous cell carcinoma. *Oral Oncology, 45*(8), 661-664.

Ajaz S, Muneer R, Siddiqa A, Memon MA, Firasat S, Abid A, Khaliq S, (2021). Strong and Significant Associations of Single Nucleotide Variants (SNVs) in the Promoter and 3'-Untranslated Region (3'-UTR) of Vascular Endothelial Growth Factor (VEGF) Gene with Head and Neck Cancers. medRxiv 2021.03.02.21252743; doi: https://doi.org/10.1101/2021.03.02.21252743

Bergh J. Analysis of the p53 Status of Tumors : An Overview of Methods. Methods Mol Med. 1999;28:179-99. doi: 10.1385/1-59259-687-8:179. PMID: 21374038.

Bouaoun, L., Sonkin, D., Ardin, M., Hollstein, M., Byrnes, G., Zavadil, J., and Olivier, M. (2016). *TP53* variations in human cancers: new lessons from the IARC *TP53* database and genomics data. *Human Mutation, 37*(9), 865-876.

Canale, M., Petracci, E., Delmonte, A., Chiadini, E., Dazzi, C., Papi, M., Mariotti, M. (2017). Impact of *TP53* mutations on outcome in EGFR-mutated patients treated with first-line tyrosine kinase inhibitors. *Clinical Cancer Research, 23*(9), 2195-2202.

Chillemi, G., Kehrloesser, S., Bernassola, F., Desideri, A., Dötsch, V., Levine, A. J., and Melino, G. (2017). Structural evolution and dynamics of the p53 proteins. *Cold Spring Harbor Perspectives in Medicine, 7*(4), a028308.

Cortezzi, S. S., Provazzi, P. J., Sobrinho, J. S., Mann-Prado, J. C., Reis, P. c. M. P., de Freitas, S. E. N., Cury, P. c. M. (2004). Analysis of human papillomavirus prevalence and *TP53* polymorphism in head and neck squamous cell carcinomas. *Cancer Genetics and Cytogenetics, 150*(1), 44-49.

Costa, S., Pinto, D., Pereira, D., Rodrigues, H., Cameselle-Teijeiro, J., Medeiros, R., and Schmitt, F. (2008). Importance of *TP53* codon 72 and intron 3 duplication 16 bp polymorphisms in prediction of susceptibility on breast cancer. *BMC cancer, 8*(1), 32.

DiGiammarino, E. L., Lee, A. S., Cadwell, C., Zhang, W., Bothner, B., Ribeiro, R. C., Kriwacki, R. W. (2002). A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. *Nature Structural and Molecular Biology, 9*(1), 12.

Ensembl. [2] Retrieved [26.09.2019] from https://asia.ensembl.org/Homo_sapiens/Transcript/Summary?db=core;g=ENSG00000141 510;r=17:7661779-7687550;t=ENST00000617185.

Fan, R., Wu, M.-T., Miller, D., Wain, J. C., Kelsey, K. T., Wiencke, J. K., and Christiani, D. C. (2000). The p53 codon 72 polymorphism and lung cancer risk. *Cancer Epidemiology and Prevention Biomarkers, 9*(10), 1037-1042.

Fischer, N. W., Prodeus, A., Malkin, D., and Gariépy, J. (2016). p53 oligomerization status modulates cell fate decisions between growth, arrest and apoptosis. *Cell Cycle, 15*(23), 3210-3219.

Gemignani, F., Moreno, V., Landi, S., Moullan, N., Chabrier, A., Gutiérrez-Enríquez, S., Capella, G. (2004). A *TP53* polymorphism is associated with increased risk of colorectal cancer and with reduced levels of *TP53* mRNA. *Oncogene, 23*(10), 1954.

Guleria, K., Sharma, S., Manjari, M., Uppal, M. S., Singh, N. R., and Sambyal, V. (2012). p. R72P, PIN3 Ins16 bp polymorphisms of *TP53* and CCR5Δ32 in north Indian breast cancer patients. *Asian Pacific Journal of Cancer Prevention, 13*(7), 3305-3311.

Hanel, W., Marchenko, N., Xu, S., Yu, S. X., Weng, W., and Moll, U. (2013). Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis. *Cell Death and Differentiation, 20*(7), 898.

Joruiz, S. M., and Bourdon, J.-C. (2016). p53 isoforms: key regulators of the cell fate decision. *Cold Spring Harbor Perspectives in Medicine, 6*(8), a026039.

Kadia, T. M., Jain, P., Ravandi, F., Garcia-Manero, G., Andreef, M., Takahashi, K., Daver, N. G. (2016). *TP53* mutations in newly diagnosed acute myeloid leukemia: clinicomolecular characteristics, response to therapy, and outcomes. *Cancer, 122*(22), 3484-3491.

Kiraz, Y., Adan, A., Yandim, M. K., and Baran, Y. (2016). Major apoptotic mechanisms and genes involved in apoptosis. *Tumor Biology, 37*(7), 8471-8486.

Krois, A. S., Dyson, H. J., and Wright, P. E. (2018). Long-range regulation of p53 DNA binding by its intrinsically disordered N-terminal transactivation domain. *Proceedings of the National Academy of Sciences, 115*(48), E11302-E11310.

Krois, A. S., Ferreon, J. C., Martinez-Yamout, M. A., Dyson, H. J., and Wright, P. E. (2016). Recognition of the disordered p53 transactivation domain by the transcriptional adapter zinc finger domains of CREB-binding protein. *Proceedings of the National Academy of Sciences, 113*(13), E1853-E1862.

Langerød, A., Bukholm, I. R., Bregard, A., Lonning, P. E., Andersen, T. I., Rognum, T. O., Børresen-Dale, A.-L. (2002). The *TP53* codon 72 polymorphism may affect the function of *TP53* mutations in breast carcinomas but not in colorectal carcinomas. *Cancer Epidemiology and Prevention Biomarkers, 11*(12), 1684-1688.

Lee, M. K., Teoh, W. W., Phang, B. H., Tong, W. M., Wang, Z. Q., and Sabapathy, K. (2012). Cell-type, dose, and mutation-type specificity dictate mutant p53 functions in vivo. *Cancer cell, 22*(6), 751-764.

Liu, Y., Xu, F., Wang, Y., Wu, Q., Wang, B., Yao, Y., Zhang, L. (2019). Mutations in exon 8 of *TP53* are associated with shorter survival in patients with advanced lung cancer. *Oncology Letters, 18*(3), 3159-3169.

Matlashewski, G., Tuck, S., Pim, D., Lamb, P., Schneider, J., and Crawford, L. (1987). Primary structure polymorphism at amino acid residue 72 of human p53. *Molecular and Cellular Biology, 7*(2), 961-963.

Monti, P., Menichini, P., Speciale, A., Cutrona, G., Fais, F., Taiana, E., Neri, A., Bomben, R., Gentile, M., Gattei, V., Ferrarini, M., Morabito, F., & Fronza, G. (2020). Heterogeneity of *TP53* Mutations and P53 Protein Residual Function in Cancer: Does It Matter?. *Frontiers in oncology*, *10*, 593383. https://doi.org/10.3389/fonc.2020.593383

Muller, P. A., and Vousden, K. H. (2013). p53 mutations in cancer. *Nature Cell Biology, 15*(1), 2-8.

Osborne, R., Merlo, G. R., Mitsudomi, T., Venesio, T., Liscia, D., Cappa, A., Callahan, R. (1991). Mutations in the p53 gene in primary human breast cancers. *Cancer Research, 51*(22), 6194-6198.

Paskulin, D., Cunha-Filho, J., Souza, C., Bortolini, M., Hainaut, P., and Ashton-Prolla, P. (2012). *TP53* PIN3 and PEX4 polymorphisms and infertility associated with endometriosis or with post-in vitro fertilization implantation failure. *Cell Death and Disease, 3*(9), e392.

Pflaum, J., Schlosser, S., and Müller, M. (2014). p53 family and cellular stress responses in cancer. *Frontiers in Oncology, 4*, 285.

Phang, B. H., Othman, R., Bougeard, G., Chia, R. H., Frebourg, T., Tang, C. L., Sabapathy, K. (2015). Amino-terminal p53 mutations lead to expression of apoptosis proficient p47 and

prognosticate better survival, but predispose to tumorigenesis. *Proceedings of the National Academy of Sciences, 112*(46), E6349-E6358.

Pietsch, E., Humbey, O., and Murphy, M. (2006). Polymorphisms in the p53 pathway. *Oncogene, 25*(11), 1602.

Pim, D., and Banks, L. (2004). p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. *International Journal of Cancer, 108*(2), 196-199.

Raj, N., and Attardi, L. D. (2017). The transactivation domains of the p53 protein. *Cold Spring Harbor Perspectives in Medicine, 7*(1), a026047.

Russell DW, Sambrook J. Molecular cloning: a laboratory manual: Cold Spring Harbor Laboratory Cold Spring Harbor, NY; 2001

Sabapathy, K. (2015). The contrived mutant p53 oncogene–beyond loss of functions. *Frontiers in Oncology, 5*, 276.

Sabapathy, K., and Lane, D. P. (2018). Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others. *Nature Reviews Clinical Oncology, 15*(1), 13.

Sagne, C., Marcel, V., Amadou, A., Hainaut, P., Olivier, M., and Hall, J. (2013). A meta-analysis of cancer risk associated with the *TP53* intron 3 duplication polymorphism (rs17878362): geographic and tumor-specific effects. *Cell Death and Disease, 4*(2), e492.

Storey, A., Thomas, M., Kalita, A., Harwood, C., Gardiol, D., Mantovani, F., Banks, L. (1998). Role of a p53 polymorphism in the development of human papilloma-virus-associated cancer. *Nature, 393*(6682), 229.

Surget, S., Khoury, M. P., and Bourdon, J.-C. (2014). Uncovering the role of p53 splice variants in human malignancy: a clinical perspective. *OncoTargets and Therapy, 7*, 57.

WMA. (2018, 09-01-2018). WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects Retrieved from https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/

Winiecka-Klimek, M., Szybka, M., Rieske, P., Piaskowski, S., Bienkowski, M., Walczak, M., Banaszczyk, M. (2014). PIN3 duplication may be partially responsible for *TP53* haploinsufficiency. *BMC Cancer, 14*(1), 669.

Xu-Monette, Z. Y., Medeiros, L. J., Li, Y., Orlowski, R. Z., Andreeff, M., Bueso-Ramos, C. E., Young, K. H. (2012). Dysfunction of the *TP53* tumor suppressor gene in lymphoid malignancies. *Blood, 119*(16), 3668-3683.

Yoon, J.-H., Smith, L. E., Feng, Z., Tang, M.-s., Lee, C.-S., and Pfeifer, G. P. (2001). Methylated CpG dinucleotides are the preferential targets for G-to-T transversion mutations induced by benzo [a] pyrene diol epoxide in mammalian cells: similarities with the p53 mutation spectrum in smoking-associated lung cancers. *Cancer Research, 61*(19), 7110-7117.

Zhou, G., Liu, Z., and Myers, J. N. (2016). *TP53* mutations in head and neck squamous cell carcinoma and their impact on disease progression and treatment response. *Journal of Cellular Biochemistry, 117*(12), 2682-2692.

S.No		PRIMER SEQUENCES	Product Size	References
1A	*TP53* **Exons/Introns 2, 3 & 4-F**	5´-TCTCATGCTGGATCCCCACT -3´	344 bp	(IARC, 2010)
1B	*TP53* **Exons/Introns 2, 3 &4-R**	5´-AGTCAGAGGACCAGGTCCTC -3´		
2A	*TP53* **Exon4-F**	5´-TGCTCTTTTCACCCATCTAC -3´	353 bp	(IARC, 2010)
2B	*TP53* **Exon4-R**	5´-ATACGGCCAGGCATTGAAGT -3´		
3A	*TP53* **Exon6-F**	5´-GCCTCTGATTCCTCACTGAT-3´	181 bp	(IARC, 2010)
3B	*TP53* **Exon6-R**	5´-TTAACCCCTCCTCCCAGAGA-3´		
4A	*TP53* **Exons8&9-F**	5´-TTGGGAGTAGATGGAGCCT -3´	445 bp	(IARC, 2010)
4B	*TP53* **Exons8&9-R**	5´-AGTGTTAGACTGGAAACTTT -3´		
5A	*TP53* **Exon11-F**	5´-AGACCCTCTCACTCATGTGA -3´	247 bp	(IARC, 2010)
5B	*TP53* **Exon11-R**	5´-TGACGCACACCTATTGCAAG -3´		

Table 1 Primer sequences of the *TP53* exons.

Table 2 Analysis of *TP53* exons in HNC patients

S.No.	*TP53* polymorphisms and mutations	Number of samples analyzed*	Number of samples with Polymorphism (%)
1		*TP53* Introns 2-3 and 3-4	
1a	PIN3 duplication (Intron 3-4)	21	20 (95.2%)
1b	C>G (intron 2-3)	21	19 (90.5%)
2		*TP53* Exon 4	
2a	exon 4 C>G (rs1042522)	15	14 (93.4%)
3		*TP53* Exon 6	
3a	Exon 6	15	0 (0%)
4		*TP53* Exon 8	
4a	Exon 8	12	0 (0%)
5		*TP53* Exon 9	
5a	Exon 9	12	0 (0%)
5		*TP53* Exon 11 and 3'UTR	
5a	3'UTR gDNA7669374_5delCC	30	4 (13.4%)

*Sequencing results were analyzed for the listed number of samples

Figure Caption

Figure 1: *TP53* gene and p53 protein functional domains. Nuclear Export Signal (NES) are present on TAD and OD. Posttranslational modification of p53 includes Phosphorylation (P), Ubiquitination (U), Acetylation (A), Sumoylation (S), Methylation (M), Neddylation (N), [adapted from (Xu-Monette et al., 2012)].